Pathogenesis and therapy of inclusion body myositis

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 630-639

  Greenberg, Steven A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

inclusion body myositis; inflammatory myopathy; muscle atrophy; myositis

Indexed keywords

ALEMTUZUMAB; ARIMOCLOMOL; AUTOANTIBODY; AZATHIOPRINE; BETA INTERFERON; BYM 338; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN; LITHIUM; METHOTREXATE; MUSCLE ANTIGEN; OXANDROLONE; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; INCLUSION BODY MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; REVIEW; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; CELL NUCLEUS; HUMANS; IMMUNOTHERAPY; MYOSITIS, INCLUSION BODY; NERVE TISSUE PROTEINS; NEUROMUSCULAR AGENTS;

EID: 84866329572     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357f211     Document Type: Review

References (72)

1. Chous SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967; 158:1453-1455.
2. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971; 25:240-248.
3. Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28:8-17. (Pubitemid 8272513)
4. Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010; 12:221-228.
5. Greenberg SA. Inclusion body myositis. Curr Opin Rheumatol 2011; 23:574-578.
6. Oflazer PS, Deymeer F, Parman Y. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey. Acta Myol 2011; 30:34-36.
7. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55:1385-1387.
8. Suzuki N, Aoki M, Mori-Yoshimura M, et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan. J Neurol 2012; 259:554-556.
9. Felice KJ, North WA. Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period. Medicine (Baltimore) 2001; 80:320-327. (Pubitemid 32879294)
10. Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008; 15:1350-1353.
11. Wilson FC, Ytterberg SR, St Sauver JL, Reed AM. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol 2008; 35:445-447. (Pubitemid 351374418)
12. Hu J, Li N, Yuan JH, et al. [A clinical and pathological analysis of inclusion body myositis]. Zhonghua Nei Ke Za Zhi 2007; 46:658-660.
13. Park SH, Park HR. Inclusion body myositis: a case report. J Korean Med Sci 1996; 11:358-363. (Pubitemid 126700884)
14. Mastaglia FL. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. Acta Myol 2009; 28:66-71.
15. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study. Muscle Nerve 2001; 24:1526-1534. (Pubitemid 32995589)
16. Cox FM, Titulaer MJ, Sont JK, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134 (Pt 11): 3167-3175.
17. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134:3176-3184.
18. Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29:1897-1906. (Pubitemid 34988698)
19. Cox FM, Reijnierse M, van Rijswijk CS, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) 2011; 50:1153-1161.
20. Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008; 79:1056-1060.
21. Felice KJ, Relva GM, Conway SR. Further observations on forearm flexor weakness in inclusion body myositis. Muscle Nerve 1998; 21:659-661. (Pubitemid 28185899)
22. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009; 339:b2680.
23. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 2007; 69:2008-2019. (Pubitemid 350145093)
24. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16:209-215. (Pubitemid 14062667)
25. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988; 23:168-173. (Pubitemid 18081455)
26. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. V: identification and quantitation of T8 + cytotoxic and T8 + suppressor cells. Ann Neurol 1988; 23:493-499.
27. Higgs BW, Zhu W, Richman L, et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012; 15:25-35.
28. De Paepe B, Creus KK. De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009; 21:610-616.
29. Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000; 2:216-224.
30. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003; 28:659-682. (Pubitemid 37484828)
31. Isenberg DA, Rowe D, Shearer M, et al. Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol 1986; 63:450-458. (Pubitemid 16155821)
32. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20:224-231. (Pubitemid 19081957)
33. Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170-1182. (Pubitemid 35192386)
34. Ivanidze J, Hoffmann R, Lochmuller H, et al. Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-gamma signaling cascade in attacked versus nonattacked myofibers. Am J Pathol 2011; 179:1347-1359.
35. Morosetti R, Gliubizzi C, Sancricca C, et al. TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis. Am J Pathol 2012; 180:1603-1613.
36. Bradshaw EM, Orihuela A, McArdel SL, et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007; 178:547-556. (Pubitemid 46033639)
37. Salajegheh M, Pinkus JL, Amato AA, et al. Permissive environment for B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve 2010; 42:576-583.
38. Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005; 65:1782-1787.
39. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16:193-208. (Pubitemid 14062666)
40. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16:692-699. (Pubitemid 39425542)
41. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184:134-153.
42. Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS One 2011; 6:e20266.
43. Greenberg SA, Pinkus JL, Amato AA. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis. Muscle Nerve 2006; 34:406-416. (Pubitemid 44506707)
44. Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40:19-31.
45. Carpenter S. Inclusion body myositis, a review. J Neuropathol Exp Neurol 1996; 55:1105-1114. (Pubitemid 26372787)
46. Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a singlestranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144:874-882. (Pubitemid 24160628)
47. Sarkozi E, Askanas V, Johnson SA, Engel WK. Alvarez RB. beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. Neuroreport 1993; 4:815-818. (Pubitemid 23190926)
48. Olive M, Janue A, Moreno D, et al. TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009; 68:262-273.
49. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79:1186-1189.
50. Kusters B, van Hoeve BJ, Schelhaas HJ, et al. TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathol 2009; 117:209-211.
51. Ritson GP, Custer SK, Freibaum BD, et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 2010; 30:7729-7739.
52. Nakano S, Shinde A, Fujita K, et al. Histone H1 is released from myonuclei and present in rimmed vacuoles with DNA in inclusion body myositis. Neuromuscul Disord 2008; 18:27-33. (Pubitemid 351173839)
53. Nishii M, Nakano S, Nakamura S, et al. Myonuclear breakdown in sporadic inclusion body myositis is accompanied by DNA double strand breaks. Neuromuscul Disord 2011; 21:345-352.
54. Parker KC, Kong SW, Walsh RJ, et al. Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve 2009; 39: 739-753.
55. Parker KC, Walsh RJ, Salajegheh M, et al. Characterization of human skeletal muscle biopsy samples using shotgun proteomics. J Proteome Res 2009; 8:3265-3277.
56. Doppler K, Lindner A, Schü tz W, et al. Gain and loss of extracellular molecules in sporadic inclusion body myositis and polymyositis: a proteomics-based study. Brain Pathol 2012; 22:32-40.
57. Derk CT, Vivino FB, Kenyon L, Mandel S. Inclusion body myositis in connective tissue disorders: case report and review of the literature. Clin Rheumatol 2003; 22:324-328. (Pubitemid 37483629)
58. Rojana-udomsart A, Needham M, Luo YB, et al. The association of sporadic inclusion body myositis and Sjogren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg 2011; 113:559-563.
59. Spector SA, Lemmer JT, Koffman BM, et al. Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle nerve 1997; 20:1242-1248. (Pubitemid 27415512)
60. Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med 2003; 35:31-35. (Pubitemid 36204070)
61. Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis 2009; 10:178-184.
62. Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012; 24:201-207.
63. Rutkove SB, Parker RA, Nardin RA, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58:1081-1087. (Pubitemid 34298550)
64. Efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis. http://clinicaltrialsgov/ct2/show/NCT01423110. [Accessed 8 January 2012]
65. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with highdose intravenous immunoglobulin. Neurology 1993; 43:876-879. (Pubitemid 23150554)
66. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44:1516-1518. (Pubitemid 24247450)
67. DalakasMC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48:712-716. (Pubitemid 27120112)
68. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247:22-28. (Pubitemid 30162508)
69. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56:323-327. (Pubitemid 32144142)
70. Rose MR, McDermott MP, Thornton CA, et al. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001; 57:548-550. (Pubitemid 32757615)
71. Lowes LP, Alfano L, Viollet L, et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 2012; 45:163-168.
72. Mendell JR, Csimma C, McDonald CM, et al. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve 2007; 35:8-16. (Pubitemid 46061362)